184 related articles for article (PubMed ID: 34235639)
1. N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
Bottemanne P; Guillemot-Legris O; Paquot A; Masquelier J; Malamas M; Makriyannis A; Alhouayek M; Muccioli GG
Neurotherapeutics; 2021 Jul; 18(3):1815-1833. PubMed ID: 34235639
[TBL] [Abstract][Full Text] [Related]
2. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
3. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Alhouayek M; Bottemanne P; Subramanian KV; Lambert DM; Makriyannis A; Cani PD; Muccioli GG
FASEB J; 2015 Feb; 29(2):650-61. PubMed ID: 25384424
[TBL] [Abstract][Full Text] [Related]
4. N-Acylethanolamine Acid Amidase contributes to disease progression in a mouse model of multiple sclerosis.
Pontis S; Palese F; Summa M; Realini N; Lanfranco M; De Mei C; Piomelli D
Pharmacol Res; 2020 Oct; 160():105064. PubMed ID: 32634582
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
[TBL] [Abstract][Full Text] [Related]
6. N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities.
Bottemanne P; Muccioli GG; Alhouayek M
Drug Discov Today; 2018 Aug; 23(8):1520-1529. PubMed ID: 29567427
[TBL] [Abstract][Full Text] [Related]
7. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages.
Sun YX; Tsuboi K; Zhao LY; Okamoto Y; Lambert DM; Ueda N
Biochim Biophys Acta; 2005 Oct; 1736(3):211-20. PubMed ID: 16154384
[TBL] [Abstract][Full Text] [Related]
8. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
Bandiera T; Ponzano S; Piomelli D
Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
[TBL] [Abstract][Full Text] [Related]
9. Lipophilic amines as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase.
Yamano Y; Tsuboi K; Hozaki Y; Takahashi K; Jin XH; Ueda N; Wada A
Bioorg Med Chem; 2012 Jun; 20(11):3658-65. PubMed ID: 22542283
[TBL] [Abstract][Full Text] [Related]
10. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Ueda N; Tsuboi K; Uyama T
Prog Lipid Res; 2010 Oct; 49(4):299-315. PubMed ID: 20152858
[TBL] [Abstract][Full Text] [Related]
11. The N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tsuboi K; Takezaki N; Ueda N
Chem Biodivers; 2007 Aug; 4(8):1914-25. PubMed ID: 17712833
[TBL] [Abstract][Full Text] [Related]
12. Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tai T; Tsuboi K; Uyama T; Masuda K; Cravatt BF; Houchi H; Ueda N
ACS Chem Neurosci; 2012 May; 3(5):379-85. PubMed ID: 22860206
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of N-acylethanolamine-hydrolyzing acid amidase reduces TÂ cell infiltration in a mouse model of multiple sclerosis.
Sgroi S; Romeo E; Fruscia PD; Porceddu PF; Russo D; Realini N; Albanesi E; Bandiera T; Bertozzi F; Reggiani A
Pharmacol Res; 2021 Oct; 172():105816. PubMed ID: 34391933
[TBL] [Abstract][Full Text] [Related]
14.
Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
[No Abstract] [Full Text] [Related]
15. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase.
Tsuboi K; Sun YX; Okamoto Y; Araki N; Tonai T; Ueda N
J Biol Chem; 2005 Mar; 280(12):11082-92. PubMed ID: 15655246
[TBL] [Abstract][Full Text] [Related]
16. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
17. Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells.
Wang J; Zhao LY; Uyama T; Tsuboi K; Wu XX; Kakehi Y; Ueda N
J Biochem; 2008 Nov; 144(5):685-90. PubMed ID: 18806270
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-restricted anti-inflammatory activities of a N-acylethanolamine acid amidase (NAAA) inhibitor F215.
Li Y; Zhou P; Chen H; Chen Q; Kuang X; Lu C; Ren J; Qiu Y
Pharmacol Res; 2018 Jun; 132():7-14. PubMed ID: 29572189
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.
Saturnino C; Petrosino S; Ligresti A; Palladino C; De Martino G; Bisogno T; Di Marzo V
Bioorg Med Chem Lett; 2010 Feb; 20(3):1210-3. PubMed ID: 20022504
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antinociceptive effects of concomitant NAAA and peripheral FAAH inhibition.
Mabou Tagne A; Fotio Y; Uppal PS; Piomelli D
Exp Neurol; 2022 Nov; 357():114194. PubMed ID: 35932800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
